You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial
|
|---|---|
| Published in |
Arthritis Research & Therapy, April 2015
|
| DOI | 10.1186/s13075-015-0611-8 |
| Pubmed ID | |
| Authors |
Patrick Verschueren, Diederik De Cock, Luk Corluy, Rik Joos, Christine Langenaken, Veerle Taelman, Frank Raeman, Isabelle Ravelingien, Klaas Vandevyvere, Jan Lenaerts, Elke Geens, Piet Geusens, Johan Vanhoof, Anne Durnez, Jan Remans, Bert Vander Cruyssen, Els Van Essche, An Sileghem, Griet De Brabanter, Johan Joly, Kristien Van der Elst, Sabrina Meyfroidt, Rene Westhovens, on behalf of the CareRA study group |
| Abstract |
Considering a lack of efficacy data in patients with early Rheumatoid Arthritis (eRA) presenting without classical poor prognosis markers, we compared methotrexate (MTX) with or without step-down glucocorticoids in the Care for early RA (CareRA) trial. Disease Modifying Anti-Rheumatic Drugs (DMARDs) naïve eRA patients were stratified into a low-risk group based on prognostic markers including non-erosiveness, Anti-Citrullinated-Protein Antibodies (ACPA) and Rheumatoid Factor (RF) negativity and low disease activity (DAS28(CRP) ≤ 3.2). Patients were randomized to 15 mg MTX weekly (MTX-TSU) or 15 mg MTX weekly with prednisone bridging, starting at 30 mg and tapered to 5 mg daily from week 6 (Cobra Slim). A tight step-up (TSU) approach was applied. Outcomes were DAS28(CRP) remission, cumulative disease activity, Health Assessment Questionnaire (HAQ) and adverse events (AEs) after 16 treatment weeks. 43 Cobra Slim and 47 MTX-TSU patients were analyzed: 65.1% in the Cobra Slim group and 46.8% in the MTX-TSU group reached remission (p = 0.081). Mean ± SD AUC-DAS28(CRP) was 13.84 ± 4.58 and 11.18 ± 4.25 for the MTX-TSU and Cobra Slim patients respectively (p = 0.006). More Cobra Slim patients had a HAQ = 0 (51.2% vs 23.4%, p = 0.006) at week 16. Therapy related AEs did not differ. In patients with low-risk eRA, MTX with step-down glucocorticoid bridging seems more efficacious than MTX step-up monotherapy with a comparable number of AEs over the first 16 treatment weeks. Eudract.ema.europa.eu; EudraCT number 2008-007225-39 ; registered 5 November 2008]. |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 73 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 15% |
| Researcher | 11 | 15% |
| Other | 7 | 9% |
| Student > Master | 7 | 9% |
| Student > Bachelor | 6 | 8% |
| Other | 16 | 21% |
| Unknown | 17 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Arts and Humanities | 3 | 4% |
| Nursing and Health Professions | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 10 | 13% |
| Unknown | 18 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 August 2016.
All research outputs
#17,283,763
of 25,371,288 outputs
Outputs from Arthritis Research & Therapy
#2,536
of 3,380 outputs
Outputs of similar age
#170,388
of 279,972 outputs
Outputs of similar age from Arthritis Research & Therapy
#57
of 87 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,380 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,972 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.